Comparative Pharmacology
Head-to-head clinical analysis: CEFEPIME HYDROCHLORIDE versus VELOSEF 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFEPIME HYDROCHLORIDE versus VELOSEF 125.
CEFEPIME HYDROCHLORIDE vs VELOSEF '125'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase and carboxypeptidase activity, leading to cell lysis.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, leading to cell lysis.
1-2 g IV every 8-12 hours; for uncomplicated urinary tract infections, 500 mg IV every 12 hours.
500 mg orally every 6 hours for uncomplicated infections; 1 g orally every 6 hours for more severe infections.
None Documented
None Documented
2-2.3 hours in healthy adults (prolonged to 13-15 hours in severe renal impairment; requires dosage adjustment).
Terminal elimination half-life: 0.5-1.0 hour (normal renal function); prolonged to 10-20 hours in severe renal impairment (CrCl <10 mL/min)
Primarily renal (≈85% unchanged via glomerular filtration and tubular secretion); biliary/fecal <1%.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic